Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients

• Status: Recruiting
• Trial end date: 2023-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatological disorder in childhood of unknown cause and a major cause of functional disability. Standard JIA treatment including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, methotrexate, and biological agents have considerable adverse effects in addition to their high cost. Despite the success of these treatment approaches, patients may still have active disease with other sequelae from chronic inflammation and considerable morbidity that may negatively impact patients' quality of life. Therefore, evaluating the potential benefit of alternative add-on anti-inflammatories and antioxidants might be a promising area for further research. Coenzyme Q10 (CoQ10) is a natural mitochondrial electron carrier and a powerful lipophilic antioxidant located in almost all cell membranes and plasma lipoproteins. Several preclinical studies in animal models as well as clinical trials in adult patients with rheumatoid arthritis (RA) have demonstrated the beneficial effects of CoQ10. Results show that CoQ10 can reduce the oxidative and inflammatory status as well as clinical features that characterize this systemic autoimmune disease.

Also, CoQ10 has been used safely in children before and was well tolerated. Thus, we would like to investigate the effect of CoQ10 oral supplementation in pediatric JIA patients.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Nourhan Elsherif
• Treatments: Coenzyme Q10; Ubiquinone

Criteria

Inclusion Criteria:

• Pediatric patients (<16 years old)

• Diagnosed with active JIA according to the American College of Rheumatology (ACR) 2019 guideline.

• Patients with peripheral oligo or polyarthritis.

• With more than 6-month disease duration

• Participants who have inadequate response to at least one first line standard therapy.

• Patients who have been receiving a stable treatment regimen for the past 3 months

Exclusion Criteria:

• Patients with active systemic JIA

• Patients presenting with complications (such as amyloidosis, uveitis, or glomerulonephritis)

• Patients with other chronic autoimmune disease.